Hypercalcemia of Malignancy

Detailed Overview

HCM is the most common life-threatening metabolic emergency in oncology, occurring in up to 30% of cancer patients at some point in their disease course. It implies advanced disease and a very poor prognosis, with median survival often measured in weeks to months. The most frequent mechanism is humoral hypercalcemia mediated by the tumor's secretion of Parathyroid Hormone-related Protein (PTHrP), classically seen in squamous cell carcinomas. Other mechanisms include osteolytic bone metastases and extrarenal calcitriol production. The rapid rise in calcium severely disrupts neurological, cardiovascular, and renal function, leading to coma and cardiac arrest if not aggressively managed with IV hydration and osteoclast inhibitors.

Epidemiology & Demographics

Incidence: Affects 20-30% of patients with cancer during their illness. Associated Cancers: Most commonly seen in multiple myeloma, breast cancer, lung cancer (squamous cell), and renal cell carcinoma. Age distribution: Parallels the incidence of the underlying malignancies (mostly older adults).

Etiological Mechanism

Disruption of normal calcium homeostasis by malignant cells through humoral factors or direct bone destruction.

Primary Causes

Humoral Hypercalcemia of Malignancy (80%): Tumor secretion of PTHrP (Squamous cell lung/head/neck, Renal, Breast)

Osteolytic Metastases (20%): Direct bone destruction by tumor cells releasing local cytokines like RANKL (Breast, Multiple Myeloma)

Calcitriol Secretion (<1%): Tumor expressing 1-alpha-hydroxylase producing active Vitamin D (Lymphomas)

• Advanced Cancer Stage: Almost exclusively occurs in stage IV metastatic disease.
• Specific Histologies: Squamous cell carcinomas (lung, head/neck, esophagus) have the highest propensity for secreting PTHrP.
• Extensive Bone Metastases: High tumor burden in the skeleton rapidly breaks down calcium-rich bone matrix.

In Humoral Hypercalcemia of Malignancy (the most common form), the primary tumor secretes PTHrP. PTHrP shares structural homology with the N-terminus of normal parathyroid hormone (PTH) and binds to the same PTH-1 receptor in bones and kidneys. In the bone, PTHrP heavily upregulates RANKL expression on osteoblasts, which activates osteoclasts, leading to massive, uncoupled bone resorption and calcium release into the blood. In the kidney, PTHrP increases distal tubular reabsorption of calcium. Crucially, the extreme calcium load causes nephrogenic diabetes insipidus (blocking ADH action), leading to profound polyuria. The resulting severe dehydration shrinks the intravascular volume, drastically reducing the GFR. This 'calcium-induced volume depletion' further prevents the kidneys from excreting the excess calcium, creating a rapid, lethal positive feedback loop.

Characteristic Clinical Presentation

• Profound Lethargy and Confusion: Progressive neurological depression, starting as fatigue and leading to stupor and coma ('moans').
• Polyuria and Polydipsia: Excessive urination due to calcium-induced nephrogenic diabetes insipidus, causing severe thirst.
• Severe Constipation and Nausea: Decreased gastrointestinal smooth muscle motility and central nausea ('groans').
• Bone Pain: Significant localized pain if osteolytic metastases are the underlying cause ('bones').

Physical Examination Signs

• Signs of severe volume depletion (dry mucous membranes, tachycardia, hypotension, poor skin turgor)
• Hyporeflexia and severe muscle weakness
• Altered mental status ranging from acute delirium to coma
• ECG changes: Shortened QT interval, potentially leading to ventricular arrhythmias

• Cardiac Arrest: Severe hypercalcemia causes a shortened refractory period, leading to ventricular fibrillation or asystole.
• Acute Kidney Injury (AKI): Prerenal failure from massive dehydration combined with direct calcium-induced renal vasoconstriction.
• Coma: Complete suppression of neuronal excitability.

Diagnostic Criteria & Guidelines

Diagnosis requires an elevated serum corrected calcium (>10.5 mg/dL) or ionized calcium, accompanied by a suppressed intact PTH level (<20 pg/mL) in a patient with known or suspected malignancy. Calcium must be corrected for hypoalbuminemia (Corrected Ca = Total Ca + 0.8 * (4 - Albumin)).

Differential Diagnosis

• Primary Hyperparathyroidism (the most common cause of hypercalcemia in outpatients; PTH will be high)
• Vitamin D Intoxication
• Thiazide Diuretic Use
• Sarcoidosis (macrophages produce calcitriol)

Laboratory Tests & Biomarkers

• Corrected Serum Calcium: Elevated, typically > 13-14 mg/dL in symptomatic patients.
• Intact Parathyroid Hormone (PTH): Appropriately suppressed (near zero) by the hypercalcemia.
• PTH-related Protein (PTHrP): Elevated in 80% of cases (confirms humoral etiology).
• BUN/Creatinine: Elevated, reflecting significant prerenal azotemia.

Imaging Modalities & Findings

• ECG:
• Bone Scan / Skeletal Survey:

• Mild
  Corrected calcium 10.5 to 11.9 mg/dL. Often asymptomatic.
• Moderate
  Corrected calcium 12.0 to 13.9 mg/dL. Symptoms of polyuria, constipation, and mild lethargy.
• Severe
  Corrected calcium >= 14.0 mg/dL. Coma, cardiac dysrhythmias, and severe acute kidney injury.

Second-Line & Adjunctive Therapy

Subcutaneous Calcitonin (4 IU/kg every 12 hours) works rapidly within hours to lower calcium via tachyphylaxis, bridging the gap until bisphosphonates work. Denosumab (120 mg SC) is used for bisphosphonate-refractory hypercalcemia. For calcitriol-mediated hypercalcemia (lymphoma), use Glucocorticoids (Prednisone 40-60 mg daily).

Surgical & Procedural Management

None specifically for the hypercalcemia. Treatment focuses on medical management and eventually treating the underlying tumor.

Recommended Lifestyle Changes

• Do not restrict dietary calcium, as this does not affect tumor-driven hypercalcemia and may worsen bone health
• Maintain high oral fluid intake if able to swallow safely
• Strictly avoid thiazide diuretics, lithium, and calcium/Vitamin D supplements

Patient Counseling & Advice

Since this syndrome usually occurs in advanced, end-stage cancer, discussions must heavily involve prognosis and goals of care. Discuss that while the IV fluids will wake the patient up and relieve symptoms temporarily, the hypercalcemia will likely return unless the underlying cancer responds to chemotherapy.

Follow-Up & Monitoring Schedule

Check serum calcium, albumin, phosphorus, and renal function every 12-24 hours during acute treatment. Long-term, monitor calcium levels monthly. Denosumab or Zoledronic acid may be given monthly to prevent recurrence.

Preventive Strategies

Routine use of bone-modifying agents (monthly Zoledronic acid or Denosumab) in patients with known bone metastases to prevent skeletal-related events, including hypercalcemia.

Extremely poor. The onset of HCM usually signifies end-stage disease. Without effective antineoplastic therapy to target the underlying tumor, the median survival from the onset of HCM is approximately 1 to 3 months.